Sacral neuromodulation is a treatment method used in the treatment of urge urinary incontinence, non-obstructive urinary retention and interstitial cystitis (bladder pain syndrome) resistant to medical therapy. Although the exact effect of neuromodulation on the voiding reflex is not yet clear, there are some theories and findings. One of these theories is the augmentation of inhibitory somatic afferent signals, which is claimed to be less in patients with overactive bladder. These afferent fibers reach the pontine voiding center and regulate the voiding reflex with chronic stimulation. After the ideal patient selection, there is a test period that can technically be done with either a temporary electrode (monopolar, PNE) or a permanent threaded (quadripolar) electrode. This test period usually ranges from 10 days to 15 days. If the patient’s clinical response to the test period is greater than 50%, second-stage implantation is performed for the permanent battery and a permanent stimulator or generator (IPG) is placed with the quadripolar electrode. Success rates vary between 64% and 88% in patients with urgency and urge incontinence or in refractory cases with a diagnosis of overactive bladder. It was observed that 72% of the patients with urinary retention were able to urinate spontaneously with an average residual urine volume of 100 ml. Implant revision rate was reported as 33%. The most common indications for reoperation are stimulator displacement and pain, electrode migration, and infection. Sacral neurostimulation is an effective treatment method with a very high success rate. Despite the significant improvement in the clinic and quality of life of the patients, the relatively high SNM side-effect profile and reintervention rates seem to be the disadvantage of SNM.